Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share allocation transactions within a retirement plan.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, an increase in the notional allocation of Ordinary share ADRs occurred on February 16, 2012. The transaction price was $44.98 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: February 16, 2012 (Notification date: February 17, 2012).
- Transaction Price: $44.98 per ADR.
- Participants and Allocations:
- Dr M M Slaoui: 15 ADRs (Connected Person: Dr K Slaoui, 12 ADRs).
- Mr W C Louv: 25 ADRs.
- Dr D Pulman: 44 ADRs.
- Mr E J Gray: 32 ADRs.
- Mrs D P Connelly: 2 ADRs.
- Context: These are notional allocations within a retirement plan, not direct market purchases by the individuals.